Bristol Myers Squibb (CELG-RI) Cost of Revenue (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Cost of Revenue data on file, last reported at $3.4 billion in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.4 billion, up 12.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 billion (up 1.82% YoY), and the FY2025 annual result was $13.9 billion, changed 0.23% from the prior year.
• Cost of Revenue retreated to $3.4 billion in Q1 2026 per CELG-RI's latest filing, from $4.1 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $4.8 billion in Q4 2024 and troughed at $2.4 billion in Q3 2022.
• A 5-year average of $3.1 billion and a median of $2.9 billion in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2024 and 2025: Cost of Revenue soared 75.3% in 2024, then fell 14.86% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $2.6 billion in 2022, then grew by 5.86% to $2.7 billion in 2023, then soared by 75.3% to $4.8 billion in 2024, then dropped by 14.86% to $4.1 billion in 2025, then declined by 16.5% to $3.4 billion in 2026.
• Business Quant data shows CELG-RI's Cost of Revenue at $3.4 billion in Q1 2026, $4.1 billion in Q4 2025, and $3.4 billion in Q3 2025.